Diabetes drug may not reduce risk of death
18 April 2018 | By European Pharmaceutical Review
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings...
List view / Grid view
Imperial College London
Researchers to investigate screening for prostate cancer using MRI
6 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately...
EC approves Alofisel for complex perianal fistulae in Crohn’s disease
3 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The EC has approved Alofisel for the treatment of complex perianal fistulae in adult patients with nonactive/mildly active luminal Crohn’s disease...
MLE490 reduces the number and severity of hot flushes in menopause
15 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days...
£54 million funding to transform health through data science
8 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Health Data Research UK is awarding £30 million funding to six sites across the UK to address challenging healthcare issues through the use of data science...
3D printing technique creates super soft biological structures
10 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new 3D printing technique allows researchers to replicate biological structures, which could be used for tissue regeneration and replica organs...
Pembrolizumab shows hope for cancerous gestational trophoblastic disease
24 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
An immunotherapy drug can be used to cure a rare type of cancer arising from pregnancy when existing treatments have failed...
Glatiramer acetate found to fight multi-resistant bacteria
23 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Glatiramer acetate, a drug used to treat multiple sclerosis, has been found to have an effect on drug-resistant bacteria...
Biosimilar trastuzumab candidate shown similar in efficacy and safety
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
New drug reduces daily menopausal hot flushes by 73%
6 April 2017 | By Niamh Marriott, Junior Editor
In a trial carried out at Imperial College, researchers showed that women who suffered seven or more hot flushes a day could reduce the number by 73%...
Mucosis’ needle-free nasal spray vaccine for RSV trial starts
8 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Mucosis has begun a first-in-human study of its intranasal Respiratory Syncytial Virus (RSV) vaccine candidate, SynGEM, at Imperial College London...
Scientists find new streptococcus variant causing severe infections
15 July 2015 | By Victoria White
Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years...
Gene therapy offers hope for cystic fibrosis patients
3 July 2015 | By Victoria White
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial...
The role of proteomics in the development of personalised cancer medicine
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…
G protein coupled receptors – exploiting flexible conformations
3 September 2012 | By Kathryn L. Chapman, Imperial Drug Discovery Centre, Imperial College London and John B.C. Findlay & Gemma K. Kinsella, Department of Biology, National University of Ireland Maynooth
G-protein coupled receptors (GPCRs) are a diverse super-family of proteins located within the plasma membrane of eukaryotic cells which have a common architecture consisting of seven-transmembrane (7-TM) segments, connected by extracellular (ECL) and intracellular (ICL) loops. They differ from other 7-TM proteins in their ability to activate guanine-nucleotide binding proteins…
Follow: